Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the ...